Professor of Medicine and Pathology Keck School of Medicine of USC
Hematology
Dr. Howard A. Liebman, MD
|
|
Give Review
Dr. Howard A. Liebman is an expert in the field of Hematology. He studied medicine at Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31/72 in Research/PrimaryCare. He over the years received 2 awards: "Top Doctors:LA Area" and "Super Doctor". Howard Liebman is a published doctor. He has 98 papers published. The most current publication "The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease." He accepts all Medicare patients.
Publications
- Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
- Approach to the management of incidental Venous thromboembolic events in patients with cancer.
- Thrombocytopenia in cancer patients.
- Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed Immune thrombocytopenia: a phase I study.
- Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
- Predictive model of Venous thromboembolism in endometrial cancer.
- Incidental Venous thromboembolism in oncology patients.
- Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemol...
- Treating Venous thromboembolism in patients with cancer.
- Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary Embolism.
- Diagnosis and management of Immune thrombocytopenia in the era of thrombopoietin mimetics.
- What do healthcare providers ask their patients with Immune thrombocytopenia?
- Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.
- The immune thrombocytopenia Syndrome: a disorder of diverse pathogenesis and clinical presentation.
- Thyroid disease in patients with Immune thrombocytopenia.
- Tumor-derived tissue factor-bearing microparticles are associated with Venous thromboembolic events in malignancy.
- The ITP Syndrome: pathogenic and clinical diversity.
- Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative Disorders.
- Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft Thrombosis or thrombocytopenia.
- Immune thrombocytopenia (ITP): an historical perspective.
- Viral-associated Immune thrombocytopenic purpura.
- The role of oral anticoagulants in tumor biology.
- Secondary Immune thrombocytopenic purpura.
- A closer look at intravascular hemolysis (IVH) following intravenous anti-D for Immune thrombocytopenic purpura (ITP).
- Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance.
- Progressive prothrombotic State in women with advancing HIV disease.
- Current perspectives on primary prophylaxis and patient risk factors for Venous thromboembolism in the cancer patient.
- Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment.
- Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor.
- AntiCoagulation is an effective treatment for aortic mural thrombi.
- Increased T-cell colony formation in AIDS patients treated with zidovudine: a possible mechanism for increased lymphocyte number.
- Increased fibrinolysis and amyloidosis.
- Peri- and paracardial involvement in Lymphoma: a radiographic study of 11 cases.
- Successful therapy of convoluted T-lymphoblastic Lymphoma in the adult.
- Metabolism of methotrexate in man after high and conventional doses.
- Three Gaucher-disease-producing mutations in a patient with Gaucher disease: mechanism and diagnostic implications.
- American Society of Clinical Oncology guideline: recommendations for Venous thromboembolism prophylaxis and treatment in patients with cancer.
- Subcutaneous lepirudin for heparin-induced thrombocytopenia and when other anticoagulants fail: illustrative cases.
- Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.
- Pathobiology of secondary Immune thrombocytopenia.
- Other Immune thrombocytopenias.
- Clinical roundtable monograph. The oncologist's role in management of Venous thromboembolism.
- Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and ...
- Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen v...
- Ticlopidine-induced aplastic Anemia: development of chromosomal abnormalities and response to immunosuppressive therapy.
- Activated recombinant human Coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
- Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement.
- The factor V Leiden mutation increases the risk of venous Thrombosis in patients with inflammatory bowel disease.
- Tamoxifen-associated venous Thrombosis and activated protein C resistance due to factor V Leiden.
- Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay fo...
- Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review.
- Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration.
- Treatment of adult T-cell Leukemia-lymphoma with a combination of interferon alfa and zidovudine.
- Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
- pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in ...
- The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modific...
- Hepatic vitamin K-dependent carboxylation of blood-clotting proteins.
- Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase.
- Antithrombin III and anti-activated factor X activity in patients with Acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
- Severe depression of antithrombin III associated with disseminated intravascular Coagulation in women with fatty liver of pregnancy.
- Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy.
- Alcoholic hepatitis: granulocyte chemotactic factor from Mallory body-stimulated human peripheral blood mononuclear cells.
- Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine...
- Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.
- Molecular basis of Hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor.
- AIDS-related Kaposi sarcoma: findings on thallium-201 scintigraphy.
- The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.
- Hepatocellular carcinoma imaging.
- Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
- Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin.
- Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.
- Subcutaneous Kaposi's sarcoma. Thallium scan demonstration.
- AIDS in intraVenous drug users: issues related to enrollment in clinical trials.
- Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency Syndrome or AIDS-related complex. Results of a Phase I trial.
- Pulmonary Kaposi sarcoma in patients with AIDS: scintigraphic diagnosis with sequential thallium and gallium scanning.
- Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
- A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer.
- Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex. A multicenter, double-blind, placebo-...
- Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-relate...
- Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase.
- Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease.
- Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
- Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning.
- Treatment of hepatitis C related thrombocytopenia with interferon alpha.
- Deficiency of the specific granule proteins, R-binder/transcobalamin I and lactoferrin, in plasma and saliva: a new disorder.
- Acquired bleeding disorder in a patient with malignant Lymphoma: antibody-mediated prothrombin deficiency.
- Treatment of refractory antibody mediated autoimmune Disorders with an anti-CD20 monoclonal antibody (rituximab).
- Detection of lupus anticoagulant identifies patients with autoImmune haemolytic anaemia at increased risk for venous thromboembolism.
- Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
- Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative Disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
- Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic Immune thrombocytopenic purpura.
- Rituximab treatment for resistant Antiphospholipid syndrome.
- Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic proStatectomy.
- Heparin-induced thrombocytopenia: diagnosis and management.
- Anti-RhD immunoglobulin in the treatment of Immune thrombocytopenia.
- Managing cancer-related Venous thromboembolic disease: low-molecular-weight heparins and beyond.
- Efficacy of romiplostim in patients with chronic Immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Schools
University of Southern California Keck School of Medicine
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Top Doctors:LA Area
- Super Doctor
Education
-
Tufts Medical Center -
University of Southern California - LAC+USC Medical Center -
Keck School of Medicine of USC
Hospital
-
Keck Hospital of USC
Helpful Reviews
Similar Doctors
|
|
Seong H. Kim, NP |
|
Dr. Sanjay Sharma, MD |
|
|
Dr. William H. Isacoff, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah M. Larson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jijun Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael H. Rosove, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward B. Garon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chao H. Huang, MD |
|
|
Dr. Amol R. Rao, MD |
|
|
Dr. James S. Hu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sophie Song, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria E. Vergara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret K. Yu, MD |